IMMP
Price
$2.10
Change
+$0.15 (+7.69%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
275.8M
57 days until earnings call
NCNA
Price
$7.03
Change
+$1.95 (+38.39%)
Updated
Oct 7, 04:59 PM (EDT)
Capitalization
9.69M
Interact to see
Advertisement

IMMP vs NCNA

Header iconIMMP vs NCNA Comparison
Open Charts IMMP vs NCNABanner chart's image
Immutep
Price$2.10
Change+$0.15 (+7.69%)
Volume$11.16K
Capitalization275.8M
NuCana
Price$7.03
Change+$1.95 (+38.39%)
Volume$9.03K
Capitalization9.69M
IMMP vs NCNA Comparison Chart in %
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMMP vs. NCNA commentary
Oct 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMMP is a StrongBuy and NCNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 08, 2025
Stock price -- (IMMP: $1.95 vs. NCNA: $5.08)
Brand notoriety: IMMP and NCNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMMP: 209% vs. NCNA: 105%
Market capitalization -- IMMP: $275.8M vs. NCNA: $13.39M
IMMP [@Biotechnology] is valued at $275.8M. NCNA’s [@Biotechnology] market capitalization is $13.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMMP’s FA Score shows that 0 FA rating(s) are green whileNCNA’s FA Score has 1 green FA rating(s).

  • IMMP’s FA Score: 0 green, 5 red.
  • NCNA’s FA Score: 1 green, 4 red.
According to our system of comparison, NCNA is a better buy in the long-term than IMMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMMP’s TA Score shows that 6 TA indicator(s) are bullish while NCNA’s TA Score has 5 bullish TA indicator(s).

  • IMMP’s TA Score: 6 bullish, 4 bearish.
  • NCNA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both IMMP and NCNA are a good buy in the short-term.

Price Growth

IMMP (@Biotechnology) experienced а +8.94% price change this week, while NCNA (@Biotechnology) price change was +32.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was +16.24%, and the average quarterly price growth was +90.12%.

Reported Earning Dates

IMMP is expected to report earnings on Dec 03, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMMP($276M) has a higher market cap than NCNA($9.69M). IMMP YTD gains are higher at: -10.138 vs. NCNA (-97.866). NCNA has higher annual earnings (EBITDA): -20.4M vs. IMMP (-43.83M). IMMP has more cash in the bank: 159M vs. NCNA (8.44M). NCNA has less debt than IMMP: NCNA (154K) vs IMMP (1.69M). IMMP (0) and NCNA (0) have equivalent revenues.
IMMPNCNAIMMP / NCNA
Capitalization276M9.69M2,847%
EBITDA-43.83M-20.4M215%
Gain YTD-10.138-97.86610%
P/E RatioN/AN/A-
Revenue00-
Total Cash159M8.44M1,883%
Total Debt1.69M154K1,094%
FUNDAMENTALS RATINGS
IMMP vs NCNA: Fundamental Ratings
IMMP
NCNA
OUTLOOK RATING
1..100
1029
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
13
Undervalued
PROFIT vs RISK RATING
1..100
88100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4865
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for IMMP (78). This means that NCNA’s stock grew somewhat faster than IMMP’s over the last 12 months.

IMMP's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as NCNA (100). This means that IMMP’s stock grew similarly to NCNA’s over the last 12 months.

IMMP's SMR Rating (97) in the Biotechnology industry is in the same range as NCNA (100). This means that IMMP’s stock grew similarly to NCNA’s over the last 12 months.

IMMP's Price Growth Rating (48) in the Biotechnology industry is in the same range as NCNA (65). This means that IMMP’s stock grew similarly to NCNA’s over the last 12 months.

IMMP's P/E Growth Rating (100) in the Biotechnology industry is in the same range as NCNA (100). This means that IMMP’s stock grew similarly to NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMMPNCNA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 21 days ago
83%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
IMMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RSSS3.600.03
+0.84%
Research Solutions
SIBN14.49-0.01
-0.07%
SI-BONE
FA15.73-0.03
-0.19%
First Advantage Corp
BGLC5.26-0.03
-0.57%
Bionexus Gene Lab Corp
AMCR8.07-0.11
-1.34%
Amcor plc